BIOHEART-B: The IBERIS® RDN system has completed market access and the first commercial procedure in Switzerland
I'm PortAI, I can summarize articles.
BIOHEART-B announced that its Iberis® RDN system has completed market access and the first commercial procedure in Switzerland, performed by the University Hospital of Basel, with no reported complications. This system is the only renal denervation product approved for use via the radial artery and femoral artery access globally, aimed at providing outpatient procedures for patients worldwide. Antu has reached a strategic cooperation with Baisheng International Group, covering multiple regions, including the European Union, Asia-Pacific, and Latin America
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments